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Background: Interaction of integrin β3 with c-Src plays critical roles in cellular signaling which is heavily implicated in
platelet adhesion and aggregation, as well as in tumor cell proliferation and metastasis or in osteoclastic bone resorption.
Selectively blocking integrin αIIbβ3 outside-in signaling in platelets has been a focus of attention because of its effective
antithrombotic potential together with a sufficient hemostatic capacity. The myristoylated RGT peptide has been shown
to achieve this blockade by targeting the association of c-Src with the integrin β3 tail, but the lack of key information
regarding the mechanisms of action prevents this strategy from being further developed into practical antithrombotics.
Therefore, in-depth knowledge of the precise mechanisms for RGT peptide in regulating platelet function is needed to
establish the basis for a potential antithrombotic therapy by targeting c-Src.
Methods: The reduction-sensitive peptides were applied to rule out the membrane anchorage after cytoplasmic delivery.
The c-Src activity was assayed at living cell or at protein levels to assess the direct effect of RGT targeting on c-Src.
Thrombus formation under flow in the presence of cytoplasmic RGT peptide was observed by perfusing whole blood
through the collagen-coated micro-chamber.
Results: The RGT peptide did not depend on the membrane anchorage to inhibit outside-in signaling in platelets. The
myr-AC ~ CRGT peptide readily blocked agonist-induced c-Src activation by disrupting the Src/β3 association and
inhibited the RhoA activation and collagen-induced platelet aggregation in addition to the typical outside-in signaling
events. The myr-AC ~ CRGT had no direct effect on the kinase activity of c-Src in living cells as evidenced by its inability to
dissociate Csk from c-Src or to alter the phosphorylation level of c-Src Y416 and Y527, consistent results were also from
in vitro kinase assays. Under flow conditions, the myr-AC ~ CRGT peptide caused an inhibition of platelet thrombus
formation predominantly at high shear rates.
Conclusions: These findings provide novel insights into the molecular mechanisms by which the RGT peptide regulates
integrin signaling and platelet function and reinforce the potential of the RGT peptide-induced disruption of Src/β3
association as a druggable target that would finally enable in vivo and clinical studies using the structure-based small
molecular mimetics.
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Arterial thrombosis developing on the atherosclerotic le-
sions causes heart attack and stroke that are currently
the most common cause of death. Platelets play central
roles in hemostasis and in arterial thrombosis by form-
ing thrombi [1]. Considerable efforts in developing anti-
platelet or antithrombotic drugs have been directed
towards integrin αIIbβ3 since it is exclusively expressed
in the platelet/megakaryocyte lineage and serves as a
final common pathway of platelet aggregation in re-
sponse to various agonists.
Arterial thrombus formation is initiated by platelet ad-
hering to the injured vessel wall at high shear rates via
the interaction of glycoprotein Ib (GPIb) with von Will-
ebrand factor (vWF) [2]. The adherent platelets need to
be further activated primarily mediated by integrin
αIIbβ3 so as to make firm association (spreading) and to
recruit more platelets (aggregation). The αIIbβ3 activa-
tion is tightly regulated by inside-out signals initiated by
various receptor/ligand interactions such as glycoprotein
VI (GPVI)/collagen, P2Y1 or P2Y12/adenosine diphos-
phate (ADP) and protease-activated receptor (PAR)/
thrombin, etc. The transduction of inside-out signals
transforms the integrin αIIbβ3 receptor from low to high
affinity that facilitates ligand (fibrinogen) binding and
thus platelet aggregation [3]. Ligand binding to integrin
αIIbβ3 triggers outside-in signaling that promotes plate-
let cytoskeletal reorganization leading to the firm associ-
ation of platelets with the vessel wall or with each other.
Integrin αIIbβ3 bidirectional signaling is primarily
dependent on the complex and dynamic associations be-
tween the cytoplasmic proteins and the short cytoplas-
mic tail of integrin β3. For instance, talin and kindlin
bind to the β3 NxxY motifs and play central roles in
inside-out signaling [4], and the association of c-Src with
the β3 tail, the RGT residues in particular [5, 6], is ob-
ligatory for outside-in signaling [5]. The conventional
antagonists prevent ligand binding to αIIbβ3 receptor
and thus actually inhibit the platelet functions regulated
by both inside-out and outside-in signals.
Genetically manipulated mouse models with an im-
paired integrin αIIbβ3 outside-in signaling [3, 7–14]
showed a significantly compromised potential of arterial
thrombosis with a normal or only slightly prolonged
bleeding time, indicating that selective inhibition of
outside-in signaling may represent a rational antithrom-
botic strategy. Compared with the genetic manipulation,
which seems currently impossible to be applied as a
therapy, synthetic molecules with “drug-like” properties
have the capability of being developed into drugs. We
have previously established that disruption of the Src/β3
interaction by the myristoylated RGT peptide selectively
inhibited outside-in signaling [15]. A recent study also
showed that the myr-FEEERA peptide disrupted Gα13/β3 interaction, ultimately hampering c-Src activation
and thereby inhibiting outside-in signaling [16]. These
data, in light of the established mechanisms in which c-
Src is pivotal for outside-in signaling by interacting with
β3 [5, 17, 18], suggest that the Src/β3 association may be
a potential target for the development of antithrombo-
tics that do not cause excessive bleeding. The synthe-
sized molecules, such as the RGT peptide, may thus
serve as a paradigm for the conception of novel anti-
thrombotic therapies even though the peptide itself may
unlikely be directly applied as a drug.
The myristoylation modification renders the peptide
membrane permeable but concomitantly integrates the
peptide into the cell membrane that may enhance its
ability to compete with β3 for c-Src [19]. It thus became
essential to define whether the RGT peptide relies on
the membrane anchorage to exert its effects. This im-
portant feature is a very basic prerequisite for designing
further applications of the peptide or its analogues.
Activated c-Src is implicated in a wide range of cellular
functions, and there is evidence that binding of some
peptides to different domains of c-Src has direct impacts
on its kinase activity most likely because of the conform-
ational regulations. For example, Nef binding to the Src
homology 3 (SH3) domain or pYEEI to Src homology 2
(SH2) [20] induced an increased activity of Src-family ki-
nases, as well as RGT peptide binding to SH3 domain of
c-Src primed the kinase [21]. Before moving towards the
in vivo and clinical studies using the structure-based
small molecular mimetics, the consequences of the RGT
peptide, or its analogues, binding to c-Src in the context
of its kinase activity need to be carefully defined. A vast
body of experimental data, mostly in vivo, indicated
that outside-in signaling was essential to stable platelet
adhesion and aggregation [8, 9, 16], and impaired
stabilization of the developing thrombi under flow con-
ditions might most likely be ascribable to the disruption
of outside-in signaling [22, 23]. The RGT peptide has
been reported to selectively inhibit outside-in signaling
under static condition [15], whether and if so, how it in-
fluences thrombus formation under flow condition is yet
an important but unanswered question.
By using reduction-sensitive peptides, the present
study aimed to address whether the RGT peptide
depends on membrane anchorage to influence Src-
regulated signaling and whether it alters the kinase
activity of c-Src. In addition, the effect of selective
blockade of outside-in signaling in human platelets
by the RGT peptide on thrombus formation and
growth under flow was tested. These efforts allow
evaluating the potential of the intracellular delivery
of the RGT analogues for antithrombotic therapies
where an effective inhibition on thrombosis is ac-
complished together with an adequate hemostasis.
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A thorough reduction of myr-AC ~ CRGT peptide is
achieved in platelet cytoplasm
It has been established that myristoylated RGT peptide
selectively inhibited integrin αIIbβ3-mediated outside-in
signaling [15]. In order to define the underlying mecha-
nisms with respect to membrane anchorage, a cell
membrane-permeable and reduction-sensitive fluores-
cent peptide (Fig. 1a) was employed in this work. Since
the emission spectrum of FAM overlaps the excitation
spectrum of TAMRA, the physical proximity of FAM toFig. 1 Membrane-permeable and reduction-sensitive peptide produced fre
presentation shows that the reduction of disulfide bonds led to a separatio
acceptor that dequenched the fluorescence of FAM allowing detection by
reduction-sensitive fluorescent peptide. The fluorescence at 576 nm (TAMR
fluorescence quantum was calculated and presented as the mean and SD
TAMRA fluorescence ratio among peptide-treated platelets (peptide + plate
peptide (peptide). The data were measured and presented as same as in p
performed utilizing Z-stack scanning with intervals of 1.2 μm (from i to iv).
performed, scale bar represents 2 μmTAMRA is able to quench the green fluorescence of
FAM [24]. Platelets were incubated with the peptide and
the fluorescence intensity of the TAMRA and FAM in
the platelets was measured, and both were found in-
creased over time and reached a plateau phase at 60 min
(Fig. 1b). We noticed a proportional increase of two
fluorescent signals indicating a disulfide bond cleavage
upon entering the cytoplasm. The ratio of FAM to
TAMRA fluorescence quantum was therefore measured
and showed no significant difference at different incuba-
tion time (Fig. 1c) suggesting a quick cleavage of thee CRGT peptide upon entering platelet cytosol. a Schematic
n of the FAM fluorescence donor and the TAMRA fluorescence
a spectrofluorometer. b Washed platelets were treated with the
A) and 519 nm (FAM) increased over time. c The ratio of FAM/TAMRA
of three independent experiments. d Comparison of the FAM to
lets), 0.3 M β-ME-treated peptide (peptide + β-ME), or untreated
anel c. e Confocal analysis of the peptide-treated platelets were
Images are from a single experiment representative of three so
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tive potential in platelet cytosol similar to the effect of
0.3 M of β-mercaptoethanol (β-ME) (Fig. 1d). Such a
vigorous reduction of disulfide bond of the internalized
peptide in platelet cytosol precludes a scenario in which
the membrane-integrated myr-AC ~ CRGT is able to
retain its CRGT moiety so as to associate with the
membrane. Confocal microscopic results from plate-
lets treated for 60 min also showed that both green
FAM and red TAMRA existed homogeneously in the
cytoplasm (Fig. 1e), indicating a dynamic balance of
the myristoylation moiety between staying membrane-
bound and in cytoplasm as shown in previous reports
[15, 25, 26].
Activated c-Src directly phosphorylates β3 Y747 and Y759
independent of its binding to the RGT sequence of the
β3 tail
The RGT sequence of the β3 tail mediated a direct inter-
action with the SH3 domain of c-Src that is critical for
outside-in signaling [5] and the activated c-Src phos-
phorylated the tyrosines of the integrin β3 tail [27] that
were confirmed by our current observations (Additional
file 1: Figure S1). We thus asked whether the kinase re-
quires binding to the β3 RGT sequence to achieve this
phosphorylation action. The mutated β3 cytoplasmic
peptides devoid of the RGT sequence (Fig. 2a) were
employed. The mass spectrometry results (Fig. 2b) and
[γ-32P] adenosine triphosphate (ATP) incorporation as-
says (Fig. 2c) showed that the tyrosine residue(s) could
be unequivocally phosphorylated. This catalytic process
was further confirmed in living Chinese hamster ovary
(CHO) cells bearing Tac-β3-ΔRGT chimeras and c-Src
Y527F (Fig. 2d). Co-immunoprecipitation data demon-
strated that the c-Src Y527F formed a complex with Tac-
β3 but not with Tac-β3-ΔRGT (Fig. 3a). The CHO cells
expressing c-Src Y527F and Tac-β3 were treated with
myr-AC ~ CRGT peptide and results showed that the
disruption of the c-Src Y527F interaction with β3 by myr-
AC ~ CRGT (Fig. 3b) did not attenuate the phosphoryl-
ation of the Y747 (Fig. 3c).
Myr-AC ~ CRGT peptide per se does not directly alter the
activity of c-Src
It is known that active c-Src is implicated in a wide
range of cellular functions and that Nef binding to the
SH3 domain or pYEEI to SH2 [20] induces an increased
activity of Src-family kinases, as well as RGT peptide
binding to SH3 domain of c-Src primes the kinase [21].
Given that the RGT peptide competes with β3 for c-Src
by binding to the SH3 domain, the consequences of
RGT peptide binding to c-Src with respect to its kinase
activity need to be clarified. Platelets were incubated
with different concentrations of myr-AC ~ CRGT andassayed for c-Src activity. There was no difference of
the c-Src Y416 and Y527 phosphorylation level between
myr-AC ~ CRGT-treated and control samples (Fig. 4a).
Co-immunoprecipitation with anti-β3 antibody showed
that myr-AC ~ CRGT abolished the interaction of β3
with c-Src and remarkably inhibited that with Csk
(Fig. 4b and c), while data with anti-Src antibody exhib-
ited a strong disruption of interaction of Src/β3 but not
that of Src/Csk by myr-AC ~ CRGT (Fig. 4d and e). We
further examined the effect of CRGT peptide on the ac-
tivity of c-Src with a Src kinase assay kit. In contrast to a
significant inhibition caused by PP2, CRGT did not alter
the kinase activity of c-Src (Fig. 4f ).
Myr-AC ~ CRGT inhibits agonist-induced c-Src activation
and the phosphorylation of the β3 cytoplasmic tyrosines
via separating c-Src from the β3 tail
Free CRGT in cytoplasm produced upon the internaliza-
tion of myr-AC ~ CRGT peptide is supposed to compete
with β3 for binding to c-Src and prevent the kinase from
being activated and participating in outside-in signaling.
Indeed, myr-AC ~ CRGT treatment resulted in a disas-
sociation of c-Src from β3 both in platelets (Fig. 4b) and
CHO cells (Fig. 3b). Data further show that in thrombin-
stimulated platelets, myr-AC ~ CRGT inhibited Y416
phosphorylation or Y527 dephosphorylation of c-Src in a
dose-dependent manner (Fig. 5a). In platelets, myr-AC~
CRGT (250 μM) almost completely inhibited the
thrombin-induced c-Src activation; thus, the phosphoryl-
ation of β3 Y747 and Y759 residues was abolished (Fig. 5b).
Myr-AC ~ CRGT inhibits thrombus formation under high
shear rates
The establishment of the influence of myr-AC ~ CRGT
on platelet function under static conditions (Additional
file 2: Figure S2 and Additional file 3: Figure S3) moti-
vated us to examine the contribution of selectively im-
paired outside-in signaling to platelet adhesion and
aggregation under flow conditions. The initial transient
platelet adhesion and rolling under flow are mediated by
the interaction of GPIb with collagen-bound vWF [28]
and integrin α2β1, or GPVI binding to collagen may also
contribute to this platelet/subendothelium interaction
[29]. These events mediate platelet stable adhesion
and irreversible aggregation primarily through integrin
αIIbβ3 outside-in signaling [30]. At a wall shear rate
of 1500 s−1, myr-AC ~ CRGT dose-dependently inhibited
thrombus formation up to 250 μM (Additional file 4:
Figure S4). Then, the effect of 250 μM of myr-AC ~
CRGT was further tested at different shear rates. At high
shear rate (5000 s−1 or 1500 s−1), which respectively rep-
resented flow conditions in stenotic arteries and, or in
arterioles or slightly stenotic arteries, thrombus forma-
tion in the presence of myr-AC ~ CRGT was between
Fig. 2 The RGT sequence of the β3 tail was not necessary for the direct phosphorylation of the β3 Y747 and Y759 by active c-Src. a The amino acid
sequences for the integrin β3-ΔRGT cytoplasmic peptides, or with Y759F, or Y747F mutations. b MALDI-TOF-MS results of the differently mutated β3
cytoplasmic peptides incubated with or without active c-Src. Black and blank arrows denote the new peak with one and two phosphorylated tyrosine(s),
respectively. c [γ-32P]ATP incorporation of differently mutated β3 cytoplasmic peptides by active c-Src. Results are presented as mean and SD of three
independent experiments. dWestern blot analysis of the tyrosine phosphorylation of Tac-β3-ΔRGT. The phosphorylation level of Y747 residue in CHO
cells expressing Tac-β3-ΔRGT or Tac-β3 together with activated c-Src was similar, but stronger than in those expressing only Tac-β3-ΔRGT or Tac-β3
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formation scarcely occurred (Fig. 6). Similar to the pub-
lished observations [31, 32], significantly few plateletsadhered to the surfaces under lower shear rates even in
DMSO control. At intermediate shear rate (500 s−1),
mimicking medium-sized arteries, myr-AC ~ CRGT
Fig. 4 Myr-AC ~ CRGT peptide per se did not directly alter the activity of c-Src. a Effect of myr-AC ~ CRGT on c-Src activity in platelets. The
peptide-pretreated platelets were lysed and blotted for Src-pY416, Src-pY527, Src or β3. The band intensity was quantified using the NIH Image J
software. The extent of Src Y416 or Y527phosphorylation was expressed as a ratio of Src-pY416 or Src-pY527 signals versus total Src signals. Integrin
β3 served as a loading control. b Effect of myr-AC ~ CRGT on the interaction of integrin β3 with c-Src or Csk. The peptide-pretreated platelets
were lysed and immunoprecipitated with anti-β3 antibody and then analyzed with anti-β3, anti-Src, and anti-Csk antibodies. c Densitometric
presentations of the results in panel b. d Effect of myr-AC ~ CRGT on the interaction of c-Src with integrin β3 or Csk. e Densitometric presentations of the
results in panel d. Results are shown the mean and SD of three independent experiments. f Substrate peptide KVEKIGEGTYGVVYK was mixed with purified
active c-Src in the presence or absence of the CRGT, CGRT peptides, or PP2 and then the [γ-32P]ATP incorporation was measured. Data are shown as the
mean and SD of three independent experiments
Fig. 3 Disruption of the constitutive Src-β3 association did not affect the tyrosine phosphorylation of the β3 tail by active c-Src. a Lysates of the
CHO cells expressing both Tac-β3 (or Tac-β3-ΔRGT) and c-Src Y527F were immunoprecipitated with anti-Flag antibody (for c-Src Y527F) and the
immune complexes were subjected to SDS-PAGE and blotted with an anti-Tac monoclonal antibody. Tac-β3 but not Tac-β3-ΔRGT was
co-immunoprecipitated with c-Src Y527F. b Lysates of CHO cells co-expressing Tac-β3 and c-Src Y527F pretreated with 250 μM of myr-AC ~
CRGT were immunoprecipitated by an anti-Flag antibody. The association of Src Y527F with β3 was disrupted by myr-AC ~ CRGT peptide.
c Lysates of CHO cells co-expressing Tac-β3 (or Tac-β3-ΔRGT) and c-Src Y527F pretreated with 250 μM of myr-AC ~ CRGT were analyzed
by Western blot using anti-β3-pY747 and anti-Tac antibodies. Myr-AC ~ CRGT did not affect the tyrosine phosphorylation of the β3 tail no
matter whether it contains the RGT sequences. Actin served as a loading control
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Fig. 5 Myr-AC ~ CRGT inhibited the phosphorylation of the integrin β3 cytoplasmic tyrosines in thrombin-stimulated platelets. a Effect of myr-AC ~ CRGT
on c-Src activity in platelets in response to thrombin stimulation. After an incubation with myr-AC~CRGT or myr-AC~CGRT, platelets were stimulated by
thrombin then lysed and blotted with anti-Src-pY416, anti-Src-pY527, and anti-Src antibodies. Integrin β3 served as a loading control. Results are shown as
the mean and SD of three independent experiments. b Effect of myr-AC ~ CRGT on thrombin-induced phosphorylation of the Y747 and Y759 of the β3
cytoplasmic tail. After an incubation with 250 μM of myr-AC ~ CRGT or myr-AC ~ CGRT, platelets were stimulated by thrombin (0.05 U/mL) with stirring,
then were lysed in SDS-PAGE sample buffer and analyzed by Western blot using anti-β3, anti-β3-pY747, anti-β3-pY759, or anti-β-tubulin antibodies. Untreated
platelets were used as a negative control, thrombin-stimulated platelets as a positive control, and β-Tubulin as a loading control
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inhibition by 7E3 (Fig. 6). However, at low shear rate
(125 s−1), which modeled the flow in venules, neither
myr-AC ~ CRGT nor 7E3 inhibited platelet adhesion
(Fig. 6).
Discussion
The antagonists target integrin αIIbβ3 receptor and in-
hibit thrombosis but compromise hemostasis as well.
Targeting signaling pathways instead of receptors may
reconcile this conflict. It has been established that model
animals with impaired outside-in signaling feature a re-
duced potential of thrombosis without excessive bleed-
ing, and the strategy of blocking outside-in signaling has
thus a definite advantage in designing new antithrom-
botic therapies. The myr-RGT peptide is known to be
capable of blocking outside-in signaling by targeting c-
Src and is considered as a synthetic molecule that is
closest to be developed into drugs by virtue of structure-
based analogues. However, there are key issues to be ad-
dressed before proceeding with the studies. A very pri-
mary issue is whether the inhibition of outside-in
signaling by myr-RGT peptide depends on its membrane
anchorage since a precise knowledge of the peptide
action is definitely necessary for conceiving a structural
analogue, i.e. membrane associable or not. Previous
studies indicated that the regulatory effect of the myris-
toylated peptides on the cellular biological functions de-
pends on its anchorage to cell membrane in some
reports [33, 34] whereas it seems not the case in others
[25, 26]. Glutathione is abundant in platelet cytoplasmat millimolar levels [35], which are sufficient to exhaust
the capacity of the disulfide bonds of myr-AC ~ CRGT
peptide at its working concentrations and confer an in-
ability of the CRGT peptide to associate with the myris-
toylation moiety, and thereby with the cell membrane.
In other words, the competition of the CRGT peptide
with the β3 tail for c-Src is unlikely attributed to the
proximity of these molecules achieved by their mem-
brane integration. Results showed that myr-AC ~ CRGT
peptide penetrated the cell membrane and yielded free
CRGT peptide in platelet cytoplasm (Fig. 1). This pep-
tide did not disrupt the integrity of the cell membrane
(Additional file 5: Figure S5) but did exert an inhibitory
effect on platelet spreading on immobilized fibrinogen,
clot retraction, irreversible aggregation, and P-selectin
expression, without affecting soluble fibrinogen binding
to αIIbβ3 and reversible aggregation (Additional file 2:
Figure S2 and Additional file 3: Figure S3). In contrast
to active c-Src phosphorylating β3 Y747 and Y759 inde-
pendent of its binding to the RGT sequence of the β3
tail in vitro (Fig. 2), c-Src in platelets is constitutively as-
sociated with β3 in an inactive form, and is activated
upon signaling through αIIbβ3. Once c-Src is dissociated
by myr-AC ~ CRGT from β3, it will not be activated
through signaling and is thus unable to phosphorylate
the β3 tail. Indeed, myr-AC ~ CRGT inhibited agonist-
induced c-Src activation (Fig. 5a) and attenuated the
phosphorylation of the Y747 and Y759 residues of β3 in
thrombin-stimulated platelets (Fig. 5b). These data
brought new information, in comparison with those
from myr-RGT, that the cytoplasmic existence of free
Fig. 6 Effect of myr-AC ~ CRGT on thrombus formation of human platelets at different shear rates. Calcein AM-labeled whole blood was incubated with
DMSO, myr-AC ~ CRGT (250 μM), or 7E3 prior to perfusion, and then perfused at different wall shear rates (5000, 1500, 500, or 125 s−1) for
4 min. The thrombus formation was observed and imaged under an inverted fluorescent microscope. a The representative images showed
platelet thrombi (scale bar is 100 μm). b The quantitative data were acquired as platelet-integrated total fluorescence intensity. c The
percentage of surface coverage. d The mean fluorescence intensity calibrated by surface coverage. Results are the mean and SD from
three independent experiments, and 40 visual fields were randomly chosen for each experiment. **P > 0.05; *P < 0.01
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tent capable of separating it from β3 (Figs. 3b and 4b).
This study further provides evidence that myr-AC ~
CRGT treatment did not affect the level of c-Src activa-
tion in platelets deposited on the immobilized fibrinogen
(Additional file 2: Figure S2D), but did cause a downregula-
tion of the platelet RhoA activation in clots (Additional file2: Figure S2G) as well as a substantial inhibition on
collagen-induced platelet aggregation (Additional file 2:
Figure S2H). These results suggest that the RGT peptide
regulated outside-in signaling by competing with β3 for c-
Src not necessarily owing to its membrane association but,
rather, through sequestrating c-Src and further indicated
that the membrane anchorage is thus not an issue of
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the active structure of RGT peptide.
In line with the previous reports, the present observa-
tions showed that active c-Src directly phosphorylates β3
Y747 and Y759 independent of its binding to the RGT se-
quence of the β3 tail (Fig. 2) indicating that activated c-
Src may still be able to promote αIIbβ3 signaling even
having been separated from the β3 tail and in view of
the fact that the free RGT peptide sequestrates c-Src in
cytoplasm and that some peptides binding to c-Src has
direct impact on its kinase activity [20, 21]. It became
essential to clarify whether the RGT peptide binding is
able to alter the enzymatic activity of c-Src and accord-
ingly to change the biological processes correlating with
this multi-functional kinase. Our data show that the
phosphorylation levels of Y416 and Y527 as well as the
association of Csk with c-Src were not affected in plate-
lets in the presence of free cytoplasmic CRGT peptide
(Fig. 4). In addition, in vitro assays for c-Src activity, in
which the phosphoryl transfer reaction occurs exclu-
sively on the Src substrate peptide since the CRGT pep-
tide contains no tyrosine residue, also revealed that the
CRGT peptide did not influence the potential of c-Src to
catalyze its substrates (Fig. 4f ). These results suggest that
RGT peptide binding to c-Src was unable to alter the c-
Src activity and the presence of the cytoplasmic CRGT
peptide caused primarily the dissociation of the Src/β3
interaction without a pronounced direct effect on c-Src.
This feature for the RGT peptide argues in favor of the
safety of its potential application in antithrombotic
therapies.
Thrombosis occurs in the blood stream, and the shear
forces play significant roles throughout the process. Se-
lective inhibition of outside-in signaling was achieved by
RGT peptide in human platelets based on experiments
in static conditions [15]. We thus became interested in
testing the effect of myr-AC ~ CRGT on thrombus for-
mation under flow conditions. We chose collagen to
coat the micro-chambers because it is the major compo-
nent of the subendothelial matrices and has thus been
recommended by the Biorheology Subcommittee of the
SSC of the ISTH [36]. Platelet stable adhesion and irre-
versible aggregation regulated primarily through outside-
in signaling [30] contribute to the thrombus growth
under flow. In a very recent publication [37], Stalker and
colleagues proposed a model for hemostatic plug forma-
tion in which the plugs are comprised of distinct regions
defined by the degree of platelet activation, packing
density, and stability. Platelets in the “core” are charac-
terized by contact-dependent signaling, P-selectin expos-
ure with a greater packing density while those in the
unstable “shell” are loosely packed and less activated
most likely dependent on the P2Y12 receptors. Similar
features may also exist in platelets that have undergonebidirectional or inside-out signaling through integrin
αIIbβ3, respectively. Therefore, the RGT-treated plate-
lets, in which only inside-out signals can be transduced,
may still be able to form thrombi though less stable to
resist the hydrodynamic drag forces. Indeed, at a shear
rate of 125 s−1, neither myr-AC ~ CRGT nor 7E3 af-
fected the platelet adhesion, in line with the previous ob-
servations in which thrombasthenic platelets adhered
normally to deendothelialized vessels at low shear rates
[38, 39]. The inability of myr-AC ~ CRGT to affect plate-
let adhesion and aggregation remained at the intermedi-
ate shear rates (500 s−1) in contrast to an unequivocal
inhibition induced by 7E3 (Fig. 6). At high shear rates
(1500 and 5000 s−1) myr-AC ~ CRGT partially inhibited
thrombus formation, as evidenced by the smaller and
thinner thrombi and less thrombus coverage as well
(Fig. 6), whereas 7E3 could still vigorously inhibit plate-
let adhesion and aggregation leading to a drastic de-
crease of thrombus formation either in size or in
coverage by showing only few platelets adhered on the
surfaces. This was the first application of human plate-
lets with specifically impaired outside-in signaling in
such an observation indicating that the Src-regulated
outside-in signaling played a pivotal role in inducing the
firm linkage of platelets to the subendothelial matrices
and to each other which renders the growing thrombi
more resistant to the drag forces. Hemostasis usually oc-
curs in small vessels such as arterioles, capillaries, and
venules [40] where blood loss will end as long as small
numbers of platelets accumulate at the sites of injury
[37]. The flow experimental data allow us to infer that in
venules (<500 s−1), myr-AC ~ CRGT-treated platelets
may adhere normally, while in arterioles and capillaries
(1500 s−1 or greater), the unaffected inside-out signaling
may still enable these platelets to form thrombi to a size
sufficient to seal the vessel damages in contrast to a
much more profound inhibition of 7E3 [31, 41]. This
unique effect of myr-AC ~ CRGT on thrombus forma-
tion under flow may explain the consequences of the
elimination of outside-in signaling in hemostatic poten-
tial manifested in genetically manipulated animals. Dif-
ferently, pathological thrombosis takes place in stenotic
medium-sized arteries with a luminal diameter exceed-
ing 100 μm, usually in millimeters such as coronary or
cerebral arteries. Coronary thrombosis model showed
that shear rates reached as high as 84,000 s−1 for a 65 %
stenosis by diameter [42]. Occlusion of these arteries
requires bigger and more stable thrombi formed under
these conditions. Significantly smaller and thinner
thrombi formed by myr-AC ~ CRGT-treated platelets at
high shear rates (1500 s−1 and 5000 s−1) (Fig. 6) indicate
that the diminished platelet stable adhesion and irrevers-
ible aggregation impair the stabilization and growth of
thrombi under higher flow and thus may prevent the
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in contrast to an adequate hemostatic situation that may
be achieved in normal small vessels.
Integrins are αβ heterodimers and the β3 subunit
forms αIIbβ3 and αvβ3 complexes; the former is
expressed exclusively in megakaryocyte/platelet lineage
and the latter is however expressed by multiple cell types
[43]. Integrin αvβ3 is also present in platelet, but only a
few hundred copies in contrast to approximately 80,000
αIIbβ3 per platelet. Disruption of the Src/β3 interaction
by the RGT peptide interferes with signal transduction
through integrin αIIbβ3 in platelets and may also affect
that through integrin αvβ3 in platelets and other cells
such as melanoma cells or osteoclasts. The influence of
the RGT-containing peptide on platelet function may be
contributed by the global action of the peptide on the
platelet β3 integrins while, as a commonly accepted con-
cept, αIIbβ3 but not αvβ3 is crucial to platelet function
owing to the overwhelming expression superiority. It
would also be interesting to look at the effect of blocking
the Src/β3 interaction in integrin αvβ3-expressing cells
on tumorogenesis or bone resorption. That would be the
goals for the future work.
Conclusions
The present study reveals novel insights into the mo-
lecular mechanisms by which c-Src regulates integrin
αIIbβ3 signaling and provides first evidence in human
platelets that the RGT peptide or its derivatives inhibit
outside-in signaling by dissociating the Src/β3 inter-
action independent of membrane anchorage. This work
lays the foundation for an in vivo validation of the effect
of RGT peptide by using membrane-permeable small
molecules derived from structure-based design and al-
lows us to anticipate that intercellular delivery of the
RGT peptide analogues may have the potential to be de-
veloped into a novel antithrombotic strategy where only
the Src/β3 interaction is specifically disrupted.
Materials and methods
Antibodies and reagents
Antibody SZ-21 specific for integrin β3 was provided by
C. Ruan (Jiangsu Institute of Hematology, Suzhou,
China) and 7E3 against integrin αIIbβ3 from J. Liu
(Shanghai Jiao Tong University School of Medicine,
Shanghai, China). Anti-Csk and anti-human IL-2 recep-
tor α antibodies were purchased from Santa Cruz Bio-
technology and R&D systems, respectively. Anti-β3-
pY747 and anti-β3-pY759 antibodies were purchased from
Abcam, and anti-Src, anti-Src-pY416, and anti-Src-pY527
antibodies were from Cell Signaling. FITC-anti-CD62P
antibody was a product of Beckman Coulter. Purified ac-
tive c-Src and the Src kinase assay kit were from Upstate
Biotechnology. Collagen type I was from Chrono-log. D-Phe-Pro-Arg chloromethylketone (PPACK) was from
Enzo Life Sciences. All other reagents were obtained
from Sigma-Aldrich.
Peptide synthesis
The cell membrane-permeable and reduction-sensitive
fluorescent peptide (FAM)myr-KACKK~ (TAMRA)CRGT
and the RGT, CRGT, CGRT, myr-AC~CRGT, myr-AC~
CGRT peptides as well as the integrin β3 cytoplasmic pep-
tides (Additional file 6: Table S1) were all synthesized by
the Chinese Peptide Company.
The cDNA constructs and cell lines
The cDNA encoding chimeric Tac-β3 was constructed
into the CMV-IL2R vector as previously described [44].
The cDNA encoding Tac-β3-ΔRGT was created using a
site-directed mutagenesis kit (Stratagene). Full-length
human c-Src cDNA was a gift from X. Gong (Zhejiang
University, Hangzhou, China). The c-Src Y527F mutant
was generated by site-directed mutagenesis, and a Flag
tag was added at the 3′ end of the c-Src Y527F sequence.
CHO cells were cultured as previously described [45].
Detection of platelet uptake of the reduction-sensitive
fluorescent peptides
Washed platelets were treated with 250 μM of (FAM)myr-
KACKK~ (TAMRA)CRGT and the time course fluores-
cence measurements (λex = 495 nm, λem= 519 nm for
FAM) were carried out using a TECAN Safire2 microplate
reader at 37 °C. To determine the efficiency of CRGT re-
lease in cytoplasm, platelets were incubated with 250 μM of
(FAM)myr-KACKK~ (TAMRA)CRGT for different time
periods, washed twice with CGS, and resuspended in
HEPES-Tyrode’s buffer. The samples were measured at 495
or 546 nm as excitation and 519 nm (FAM) or 576 nm
(TAMRA) as emission wavelength. The ratio of FAM to
TAMRA fluorescence quantum was calculated. As con-
trol of a drastic reduction, 250 μM of (FAM)myr-
KACKK ~ (TAMRA)CRGT was treated with 0.3 M of
β-ME. To further determine the distribution of the
CRGT peptide, the samples were examined with a Zeiss
LSM 510 laser confocal microscope using a × 100 oil
immersion objective as previously described [25].
Phosphorylation of the tyrosines at position 747 and 759
of the integrin β3 tail by active c-Src
First, the Y747 and Y759 phosphorylation of the β3 tail
was estimated by MALDI-TOF MS. The purified β3
cytoplasmic peptides, with wild type or Y759F, Y747F,
Y747, 759 F, ΔRGT Y747F, ΔRGT Y759F, and ΔRGT mutant
sequences were dissolved in Src kinase reaction buffer.
The peptides (at a final concentration of 20 μM) in
10 μL of Src kinase reaction buffer were mixed with
purified active c-Src (1 unit) and incubated at 30 °C for
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subjected to MALDI-TOF mass spectrometry analysis
after desalted on a C18 tip and eluted with acetonitrile,
water, and trifluoroacetic acid (90/10/0.1, by volume).
The Y747 and Y759 phosphorylation of β3 was further de-
termined by a [γ-32P] incorporation assay [27]. Briefly,
The aforementioned β3 cytoplasmic peptides or a con-
trol substrate peptide KVEKIGEGTYGVVYK were incu-
bated with purified active c-Src in Src kinase reaction
buffer containing 5 μCi of [γ-32P]ATP and 10 μM of
ATP at 30 °C overnight. Reaction mixtures were trans-
ferred to P81 phosphocellulose membranes and washed
with 0.75 % phosphoric acid. These membranes were
rinsed briefly in acetone, air dried, and transferred into
scintillation vials. The [γ-32P]ATP incorporation of the
peptides were counted using a Beckman LS6500 liquid
scintillation counter (Beckman, Fullerton, CA). We also
measured β3 Y747 and Y759 phosphorylation by active
c-Src in CHO cell models. Tac-β3 or Tac-β3-ΔRGT was
transfected or co-transfected together with c-Src Y527F
at a ratio of 1:1 into CHO cells using the Lipofectamine
2000 kit (Invitrogen). Twenty-four hours later, the cells
were lysed at 4 °C in ice-cold RIPA buffer (1 % NP-40,
150 mM NaCl, 50 mM Tris, pH 7.4, 1 mM EDTA,
0.25 % sodium deoxycholate, 1 mM sodium vanadate
and 1 mM PMSF) and clarified by centrifugation at
12,000 rpm for 15 min and then were analyzed by West-
ern blot.
Platelet preparation, platelet spreading on immobilized
fibrinogen, clot retraction assay, platelet aggregation,
soluble fibrinogen binding, and P-selectin expression
Whole blood was drawn by venipuncture from healthy
volunteers with informed consent who had not taken
any medication within 2 weeks anticoagulated with 1/10
volume of 3.8 % (w/v) trisodium citrate. Platelet-rich
plasma (PRP) was obtained by a centrifugation at 200 × g
for 20 min. For preparation of washed platelets, the PRP
was acidified by adding 1/7 volume of acid citrate dex-
trose (ACD; 85 mM trisodium citrate, 83 mM dextrose
and 21 mM citric acid) and platelets were collected by a
centrifugation at 1500 × g for 20 min. The platelet sedi-
ments were washed twice with CGS (120 mM NaCl,
13 mM trisodium citrate, 30 mM glucose, pH 6.5), and
were finally resuspended at required concentrations in
HEPES-Tyrode’s buffer (137 mM NaCl, 2 mM KCl,
12 mM NaHCO3, 0.3 mM NaH2PO4, 5.5 mM glucose,
1 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, and 0.1 %
BSA, pH 7.4). The platelet suspensions were left at room
temperature for 60 min prior to being used in experi-
ments. Platelet spreading on immobilized fibrinogen was
assayed as previously described [15]. The 6-well microti-
ter plates were coated with human fibrinogen (20 μg/
mL) in 0.1 M of NaHCO3 (pH 8.3) at 4 °C overnight.Washed platelets, resuspended at a final concentration
of 1 × 108/mL in HEPES-Tyrode’s buffer, were preincu-
bated with peptides for 60 min and were then added into
the fibrinogen-coated wells and incubated at 37 °C for
45 min. The platelets were collected and lysed for
30 min at 4 °C in ice-cold RIPA buffer containing the
protease inhibitor mixture. After a centrifugation of the
platelet lysates at 12,000 rpm for 15 min, the superna-
tants were added with an equal volume of 2 × SDS
Laemmli sample buffer. Proteins were separated by SDS-
PAGE using 12 % gels, transferred to PVDF membrane
(Amersham), and immunoblotted with the antibodies
specific for human c-Src, Src phospho-tyrosine527, Src
phospho-tyrosine416, and actin. Clot retraction studies,
platelet aggregation, soluble fibrinogen binding assay,
and detection of P-selectin expression were performed
as previously described [15].
RhoA activation
Clot retraction was terminated at 60 min by the addition
of lysis buffer. RhoA activation of platelets in clots was
detected using an Active Rho Pull-Down and Detection
Kit (Pierce Biotechnology) according to the published
procedure with minor modifications [16].
In vitro assays for c-Src activity
Reactions were carried out using a Src kinase assay kit
(Upstate Biotechnology). Briefly, 150 μM of substrate
peptide KVEKIGEGTYGVVYK was mixed with purified
active c-Src in the presence or absence of CRGT, CGRT,
or PP2 in Src kinase reaction buffer containing 5 μCi of
[γ-32P]ATP and 10 μM of ATP and incubated at 30 °C
overnight. [γ-32P]ATP incorporation was counted using
a Beckman LS6500 liquid scintillation counter.
Co-immunoprecipitation and Western blot analysis
Preparation of platelet lysates or cell lysates, immuno-
precipitation, SDS-PAGE, and immunoblotting were
performed according to the procedures published else-
where [15]. In brief, the peptide-pretreated platelets,
CHO cells co-expressing Tac-β3 and c-Src Y527F, or Tac-
β3-ΔRGT and c-Src Y527F, or peptide-pretreated CHO
cells co-expressing Tac-β3 and c-Src Y527F were lysed
for 30 min at 4 °C in ice-cold RIPA buffer containing the
protease inhibitor mixture. Protein concentrations were
determined using the bicinchoninic acid protein assay
kit (Pierce Chemical). The lysates were centrifuged for
5 min at 4 °C at 12,000 rpm, and then, 100 μL aliquots
of the supernatants containing equal amounts of protein
(ranging from 400 to 500 μg between experiments) were
immunoprecipitated by the indicated antibodies for 2 h
at 4 °C with gentle agitation and were further incubated
with protein G plus-agarose beads overnight at 4 °C.
After washing three times with RIPA buffer, the
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Laemmli sample buffer and were electrophoresed with
8 % or 12 % SDS-PAGE, transferred onto PVDF mem-
brane. Proteins were detected using the indicated primary
antibodies and HRP-conjugated secondary antibodies. Im-
munoreactive bands were detected by ECL with the reac-
tion time ranging from 30 s to 5 min. The signal intensity
of the respective bands was measured by the NIH Image J
software.
Ex vivo flow-based platelet adhesion and aggregation assays
The experiments were performed as described [46]. Bio-
flux 48 well plates (Fluxionbio) were coated with 20 μg/
ml collagen at 4 °C overnight. Blood was drawn into
PPACK (at a final concentration of 150 μM), and calcein
AM (4 mM, at 37 °C for 30 min) was used to label plate-
lets in whole blood. The blood was then incubated with
peptides for 30 min at 37 °C and was perfused through
the micro-chambers at wall shear rates of 125, 500, 1500
or 5000 s−1 for 4 min. Adherent platelet aggregates were
monitored using an inverted fluorescent microscope
with a × 20 long-working-distance objective and CCD
camera (Nikon eclipse Ti-s).
Statistics
Differences between groups were assessed using the Stu-
dent’s t test. When three or more groups were com-
pared, we used ANOVA (SPSS software, version 18).
Data are presented as mean and SD, unless otherwise
specified.
Additional files
Additional file 1: Figure S1. Active c-Src directly phosphorylated the
Y747 and Y759 residues of β3. (A) The amino acid sequences for the wild
type or differently mutated integrin β3 cytoplasmic peptides. (B) MALDI-TOF
mass spectrometry results of the integrin β3 cytoplasmic peptides (wild type
or differently mutated) incubated with or without active c-Src. Black arrow
shows the new peak which represents the addition of a phosphate group to
the tyrosine of the peptides, and blank arrow shows that of two phosphate
groups to two tyrosines. (C) The Src-induced [γ-32P]ATP incorporation assays
were performed in the presence of a Src substrate peptide or different integrin
β3 cytoplasmic peptides. The [γ-32P]ATP incorporation was observed in the
peptide with tyrosine residue(s), but not in the Y747F and Y759F double
mutated peptide. The Src inhibitor PP2 (20 μM) prevented the [γ-32P]ATP
incorporation. Results are presented as mean and SD of three independent
experiments.
Additional file 2: Figure S2. Myr-AC ~ CRGT peptide impaired integrin
αIIbβ3-mediated outside-in signaling. (A) The peptide-pretreated platelets
were allowed to adhere on fibrinogen-coated coverslips for 45 min. Data
shown are representative pictures from one of three experiments with
similar results. Scale bar is 20 μm. (B) The percentage of the surface areas
covered by spreading platelets. (C) The adherent platelets after washing
were quantified by a PNPP assay. Washed platelets were incubated with
different peptides as indicated. (D) After incubation with myr-AC ~ CRGT
or control peptide and deposited on immobilized fibrinogen for 45 min,
the platelets were lysed and analyzed for the activation of c-Src by
Western blot. (E) Fibrin clot formation was initiated by adding 1 U/mL
thrombin in the presence of 2 mg/mL of human fibrinogen. The clotswere photographed at different time points. (F) The percentage of the
clot size was generated by calculating the ratio of the surface area of the
retracted clots versus that of the initial clots. The data are presented as
the mean and SD of three independent experiments. (G) The fibrin
clots containing platelets were lysed and analysed for c-Src and RhoA
activation by Western blot. (H) After an incubation with DMSO (a),
250 μM of myr-AC ~ CGRT (b), myr-AC ~ CRGT at concentrations of
62.5 μM (c), 125 μM (d) or 250 μM (e), platelet aggregation was induced
by ADP, thrombin, ristocetin, or collagen. (I) Surface expression of
P-selectin on untreated or peptide-pretreated platelets stimulated with
thrombin (0.1 U/mL). (J) The fluorescence intensity calculated from the
data in panel I is presented as the mean and SD of three independent
experiments.
Additional file 3: Figure S3. Myr-AC ~ CRGT peptide did not affect the
integrin αIIbβ3-mediated inside-out signaling. (A) Effect of myr-AC ~ CRGT
on soluble fibrinogen binding to platelets. Platelets were preincubated
with different peptides or their vehicles, and binding of Alexa Fluor
488-conjugated fibrinogen (100 μg/mL) to platelets was measured by
flow cytometry after the addition of 20 μM ADP. (B) The fluorescence
intensity calculated from the data in panel A is presented as the mean
and SD of three independent experiments.
Additional file 4: Figure S4. Myr-AC ~ CRGT dose-dependently inhibited
thrombus formation of human platelets at a shear rate of 1500 s−1. Calcein
AM-labeled whole blood was preincubated as indicated and then perfused
through a collagen-coated surface at a wall shear rate of 1500 s−1 for 4 min.
The thrombus formation was observed and imaged under an inverted
fluorescent microscope with a × 20 long-working-distance objective. (A) The
representative images showed platelet thrombi (scale bar is 100 μm). (B) The
quantitative data were acquired as platelet-integrated total fluorescence
intensity. (C) The percentage of surface coverage. (D) The mean fluorescence
intensity calibrated by surface coverage. Results are the mean and SD from
three independent experiments. *P< 0.01.
Additional file 5: Figure S5. Myr-AC ~ CRGT peptide did not cause cell
lysis. (A) Release of hemoglobin from human erythrocytes induced by
various concentrations of myr-AC ~ CRGT or the scrambled myr-AC ~
CGRT. The extent of the hemoglobin release into the supernatant was
measured at 405 nm. Triton X-100- or DMSO-treated erythrocytes served
as positive or negative controls, respectively. (B) Release of phosphatase
activity from nonaggregated platelets. Platelets were incubated with
peptide as indicated at 37 °C for 30 min in the absence of stirring. The
phosphatase activity was separately measured in platelet-free supernatant
(black bar) or platelet pellets (white bar) by using p-nitrophenyl phosphate
as a chromogenic substrate. The mean and SD were obtained from three
independent experiments.
Additional file 6: Table S1. The integrin β3 cytoplasmic peptides (wild
type or differently mutated).
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